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The effect of recombinant rat y-interferon (y-IFN) on iodide uptake and CAMP production by rat thyroid 
cells in vitro was studied using the continuously growing, functional FRTL, cell line. Both functions were 
stimulated by y-IFN at concentrations of I-10 U/ml. Iodide uptake was dependent on protein synthesis, 
since it was blocked by cycloheximide treatment, but was not dependent on growth factors in calf serum 
routinely used for FRTL, cell culture. These results show that y-IFN can stimulate thyroid cell function 
as well as aberrant Ia expression in vitro. 
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1. INTRODUCTION 
The continuously growing, differentiated rat 
thyroid cell line, FRTL5, has been used extensively 
to investigate thyroid cell function in vitro, in par- 
ticular cyclic AMP (CAMP) production and iodide 
uptake in response to recognised stimulators such 
as thyrotrophin (TSH) and TSH receptor anti- 
bodies [l-4]. Earlier work has established that 
mouse interferons stimulate both adenylate cyclase 
activity in rat thyroid membranes [5] and iodide 
uptake by FRTLs cells [6]. However, these ex- 
periments used type I P-IFN which differs in many 
respects from type II y-IFN. 
y-IFN is produced by activated T cells and has 
a wide range of immunological effects [7]. It is 
known that y-IFN is produced by activated T cells 
infiltrating the thyroid in various types of autoim- 
mune thyroiditis [S] and seems to be the key 
modulator responsible for inducing aberrant Ia an- 
tigen expression on the thyroid in these conditions, 
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whereas LY- and ,&-IFN do not have this property 
[9]. We have recently found that recombinant rat 
y-IFN will induce Ia antigens on FRTLs cells 
grown in vitro (Weetman et al., submitted) and 
have now investigated whether this type of IFN 
will modulate FRTLs iodide uptake and CAMP 
production. 
2. MATERIALS AND METHODS 
The FRTLs cells were obtained from Dr N. Mar- 
shall (University College Hospital, London) and 
used within 20 passages. They were maintained as 
described in [ I,21 in Coon’s modified Hams F-12 
medium with 5% newborn calf serum and six hor- 
mone (6H) supplements: TSH (10 mu/ml), insulin 
(10 pg/ml), cortisol ( 10e8 M), transferrin (5 pg/ 
ml), glycyl-L-histidyl-L-lysine (10 pg/ml) and 
somatostatin (10 pug/ml). 5H medium lacked TSH. 
Assays were performed in replicates of six in 
24-well plates (Nunc, Kamstrup, Denmark), after 
resting the cells for 7 days in 5H medium. In assays 
for iodine uptake, stimulators were added for 48 h 
in fresh 5H medium and iodine uptake was 
measured 1 h after the addition of 0.1 ,.Xi carrier- 
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free Nalz51, using the perchlorate discharge 
method in [lo]. The production of CAMP was 
measured over a 4 h period after addition of the 
stimulator in low-salt medium [1 I]; CAMP in the 
supernatant was determined using an in-house 
radioimmunoassay, with “‘I-CAMP kindly pro- 
vided by Dr N. Marshall. In all cases the residual 
cell mass was determined by crystal violet staining 
of the plate [12]; variation between wells was never 
greater than 7%, so no correction was made for 
cell number. Recombinant rat y-IFN [13] was ob- 
tained from Holland Biotechnology and recombi- 
nant human y-IFN from Genentech. Statistical 
evaluation was by Student’s f-test. 
3. RESULTS 
3.1. Iodide uptake 
Iodide uptake was significantly enhanced by rat 
y-IFN at concentrations as low as 0.1 pg/ml; 
human y-IFN had no effect (fig.1). Moreover, y- 
IFN had an additive effect on the iodide uptake 
stimulated by TSH (fig.2). The action of y-IFN on 
iodide uptake was sensitive to cycloheximide. Pre- 
treatment of the cells with 50yM cycloheximide 
for 1 h before the addition of 10 U y-IFN/ml for 
48 h reduced iodide uptake, expressed as a percen- 
tage increase over basal values, from 566 + 30 to 
372 f 22% (P<O.OOl). However, pretreatment 
with phorbol myristate acetate (10 or 100 ng/ml) 
had no effect on iodide accumulation (values for y- 
IFN stimulated iodide uptake within 20% of those 
for cultures with y-IFN and phorbol ester: 
P>O.O5). To examine the duration of y-IFN ex- 
posure required for an effect on iodide uptake, 7 
day cultures in 5H medium were treated with y- 
IFN for varying periods, washed 5 times and then 
culture continued in 5H medium for a total time of 
44 h. The addition of y-IFN (10 U/ml) for periods 
as short as 1 h prior to transfer to 5H medium 
alone produced a significant effect, with iodide up- 
take 19 f 10% (mean + SD) of the maximal value 
produced by continuous culture for 44 h in y-IFN. 
Exposure for 4 or 9 h gave respective iodide uptake 
values of 48 f 14 and 89 f 15% of the maximum. 
The ability of y-IFN to stimulate iodide uptake 
in serum-free medium was tested, in view of the 
possibility that constituents of the serum such as 
growth factors could be contributing to the results 
obtained. Cells were incubated in serum-free 5H 
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Fig.1. Effect of y-IFN concentration on “‘1 uptake by 
FRTLs cells. Bar represents 1 SD. * P<O.OOl vs cultures 
without y-IFN. 
medium with y-IFN at 10 U/ml and although a 
reduction in iodide uptake was observed compared 
to samples treated with y-IFN in 5H medium with 
5% calf serum (mean + SD increase in uptake over 
basal 401 f 13 vs 558 f 47%; P<O.OOl) the cells 
were nevertheless stimulated to take up iodide 
significantly (P<O.OOl vs basal control). 
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Fig.2. Effect of r-IFN on TSH-stimulated iodide uptake 
by FRTLs cells. Bar represents 1 SD. The combination 
of y-IFN plus TSH produced significantly greater 
stimulation than TSH alone (P<O.OOl). 
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Table 1 
CAMP accumulation in FRTLs supernatant 4 h after 
addition of y-IFN or TSH 
Addition CAMP production 
(pmol/culture) 
Nil 
Rat y-IFN (10 U/ml) 
(1 U/ml) 
Human T-IFN (100 U/ml) 
TSH (50 pU/ml) 
(5 pU/ml) 
TSH (50 pU/ml) + 
y-IFN (10 U/ml) 
TSH (5 pU/ml) + 
y-IFN (1 U/ml) 
a P<O.OOl vs control 
521 
32 + 3” 
26 ?z 3” 
6+1 
81 *5” 
62 -+ 5” 
116 f g8 
98 + 6” 
Results are means + SD of six replicates 
3.2. CAMP production 
The accumulation of CAMP in FRTLs super- 
natants is detailed in table 1. Both rat y-IFN and 
TSH stimulated CAMP production; there was an 
additive response when these agents were added 
together. 
4. DISCUSSION 
These results show that recombinant homolo- 
gous y-IFN stimulates iodide uptake and CAMP 
production by the rat thyroid cell line FRTL5. It is 
known that TSH mediates FRTLs iodide incor- 
poration by the CAMP second messenger system 
and that iodide uptake is also dependent on protein 
synthesis (inhibited by cycloheximide) but, unlike 
at-adrenergically regulated functions in FRTLs 
cells, is not affected by phorbol myristate acetate, 
which mimics the effect of diacylglycerol on pro- 
tein kinase C [14,15]. The effect of y-IFN on 
FRTLs cells was thus similar to TSH in these 
respects, although the kinetics of the response are 
somewhat slower since 64% of maximal iodide up- 
take is produced by TSH after exposure for only 
1 h, and maximal uptake is found after 5 h [4]. 
Recently, another cytokine of immunological 
importance, interleukin- 1, was shown to stimulate 
FRTLs DNA synthesis, although this activity was 
greatly enhanced by insulin-like growth factor- 1, a 
known constituent of the calf serum routinely used 
for FRTLs culture [16]. y-IFN was able to 
stimulate iodide uptake in the absence of calf 
serum and it is not clear at present whether the 
modest increase in stimulation seen in the presence 
of calf serum reflects a similar type of interaction 
or a non-specific effect of culture in a more op- 
timal medium. 
It has previously been found that purified (but 
not recombinant) type I IFN, apparently ,&IFN, 
stimulated iodide uptake and CAMP production by 
FRTLs cells (61. There is no structural homology 
between ,&-IFN and y-IFN (type II IFN) and their 
effects are mediated by separate receptors; 
although the two types of IFN share certain ac- 
tivities, other effects are produced by a single IFN 
species [7]. Thyroid cells clearly possess both types 
of IFN receptor in view of the present results and 
the action of y-IFN on thyroid cell Ia antigen ex- 
pression [9]. However, only y-IFN, and not cy- or 
fl-IFN, is able to mediate this latter activity ([9] 
and unpublished). It has been shown that the 
thyroid lymphocytic infiltrate in autoimmune 
thyroiditis (Graves’ disease or Hashimoto’s 
thyroiditis) is capable of producing y-IFN, respon- 
sible for the aberrant thyroid Ia antigen expression 
seen in these conditions [8,9]. The present results 
suggest that local y-IFN production by T cells 
could also have effects on thyroid function in these 
conditions. 
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